Background and Methods Aldosterone is important in the pathophysiology of heart failure. In a double-blind study, we enrolled 1663 patients who had severe heart failure and a left ventricular ejection fraction of no more than 35 percent and who were being treated with an angiotensin-converting–enzyme inhibitor, a loop diuretic, and in most cases digoxin. A total of 822 patients were randomly assigned to receive 25 mg of spironolactone daily, and 841 to receive placebo. The primary end point was death from all causes. Results The trial was discontinued early, after a mean follow-up period of 24 months, because an interim analysis determined that spironolactone was efficacious. There were 386 deaths in the placebo group (46 percent) and 284 in the spironolactone group (35 percent; relative risk of death, 0.70; 95 percent confidence interval, 0.60 to 0.82; P<0.001). This 30 percent reduction in the risk of death among patients in the spironolactone group was attributed to a lower risk of both death from prog...

https://www.nejm.org/doi/pdf/10.1056/NEJM199909023411001

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Preamble and Transition to ACC/AHA Guidelines to Reduce Cardiovascular Risk S2

The goals of the …

/pdf/2013-acc-aha-guideline-on-the-treatment-of-blood-cholesterol-pvngcav7fq.pdf

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

ACC/AHA
: American College of Cardiology/American Heart Association
ACCF/AHA
: American College of Cardiology Foundation/American Heart Association
ACE
: angiotensin-converting enzyme
ACEI
: angiotensin-converting enzyme inhibitor
ACS
: acute coronary syndrome
AF
: atrial fibrillation

/pdf/2016-esc-guidelines-for-the-diagnosis-and-treatment-of-acute-53v7yllhiz.pdf

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

ALAT
: alanine aminotransferase
ASAT
: aspartate aminotransferase
APAH
: associated pulmonary arterial hypertension
BAS
: balloon atrial septostomy
BMPR2
: bone morphogenetic protein receptor 2
BNP
: brain natriuretic peptide
BPA
: balloon pulmonary angioplasty
BREATHE
: Bosentan

/pdf/2015-esc-ers-guidelines-for-the-diagnosis-and-treatment-of-y26yabnnom.pdf

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

The aim of the study was to evaluate the time course of atrial and ventricular function improvement following internal atrial cardioversion in patients with structural heart disease. Twenty-nine patients with chronic persistent atrial fibrillation (AF) and underlying structural heart disease were followed by serial echocardiograms performed at 1 and 6 hours, 1 day, 1, 2, and 3 weeks, and 1, 2, 3, and 6 months after successful cardioversion. Sinus rhythm was maintained at 6 months in 24 patients. Following cardioversion the time course of left atrial mechanical function (peak A wave, percent A wave filling) differed from that of left ventricular ejection fraction: peak A wave values (cm/s) increased significantly at 1 week (51 +/- 23 vs 35 +/- 15 at 1 hour, P < 0.05), percent A wave filling (%) increased significantly at 2 weeks (34 +/- 12 vs 22 +/- 9 at 1 hour, P < 0.05), whereas left ventricular ejection fraction (%) increased later (at 1 month 60 +/- 14 vs 55 +/- 14 at baseline, P < 0.05 and at 2 months 60 +/- 14 vs 56 +/- 14 at 1 hour, P < 0.05). In conclusion, restoration of sinus rhythm results in an improvement in left ventricular ejection fraction during follow-up, even in patients with structural heart disease without fast ventricular rates at baseline. The dissociation between the time course of atrial and ventricular function improvement suggests that the latter was partly due to regression of a concealed form of cardiomyopathy and/or of a ventricular dysfunction due to chronic AF.

Late Improvement in Ventricular Performance Following Internal Cardioversion for Persistent Atrial Fibrillation

CT scan at his discharge. Warfarin was administered as a posttransplant anticoagulation therapy, whose aimed international normalization ratio was between 1.5 and 2.0. Microscopic findings of explanted liver consisted of typical findings of BCS, namely, centrizonal congestion, necrosis, and hemorrhage. Although many reports have shown that patients can be managed without IVC reconstruction (3–5), we believe that IVC reconstruction using a venous allograft for a pediatric BCS patient is a curative approach when the patient shows simultaneous IVC stenosis. Kazunari Sasaki Mureo Kasahara Akinari Fukuda Takanobu Shigeta Department of Transplantation Surgery National Center for Child Health and Development Tokyo, Japan

Prophylaxis versus preemptive therapy for prevention of the consequences of cytomegalovirus infection in transplant recipients: a still unresolved issue.

The 3rd World Symposium on Pulmonary Arterial Hypertension has been a forum for the presentation and discussion of overviews on several aspects of this devastating disease, including pathology and pathobiology, genetics, epidemiology, nomenclature and classification, diagnosis and assessment, medical treatments, interventional and surgical treatments and future directions. This editorial will provide a brief overview of the new findings emerging in this field including new pathologic and pathobiologic concepts, changes in the clinical classification and in the diagnostic definitions. In addition, new treatment strategies and future perspectives will be discussed.

New insights on pulmonary arterial hypertension

Aims Morphology discrimination (MD) is an algorithm based on QRS morphology analysis, that can be used alone or in various combinations with other discriminators in order to diagnose ventricular tachycardia (VT) [the implantable cardioverter-defibrillator (ICD) may be set to diagnose VT if ‘Any’ or ‘All’ the discriminators indicate VT)].

Methods and results We evaluated the contribution of MD in terms of Specificity (SP) and Sensitivity (SE) of rhythm discrimination in slow and fast VT zones (rates <150 bpm and between 150 and 180 bpm, respectively). Detection results (682 spontaneous episodes in 58 patients) were corrected for multiple episodes within a patient (generalized estimating equations method). Rhythm discrimination in slow VT zones was characterized by SE and SP below 80% without MD, while the use of MD alone allowed to enhance SP, maintaining SE at 96%. Use of MD in combination with other discriminators resulted in a decrease in SP (setting ‘Any’). In fast VT zones, MD allows an increase in SE for VT detection from around 82% up to approximately 94%, coupled with an SP of 95–96%., although SP is much higher with MD alone (94.8%) than with any other combination (78.4%). Both in slow and fast VT zones, use of multiple discriminators with the setting ‘All’ resulted in an unacceptable decrease in SE.

Conclusion MD in a dual-chamber ICD in combination with a rate branch classification system makes it possible to achieve a very high SP in discriminating detected events both in slow and fast VT zones, while maintaining SE for VT detection.

/pdf/contribution-of-morphology-discrimination-algorithm-for-2nforns9um.pdf

Contribution of morphology discrimination algorithm for improving rhythm discrimination in slow and fast ventricular tachycardia zones in dual-chamber implantable cardioverter-defibrillators.

BACKGROUND Unstable angina is usually caused by acute thrombosis superimposed on a fissured plaque. Coronary artery stenting has been shown to improve short- and long-term results of coronary angioplasty in mainly stable patients with one-vessel disease, but it is uncertain whether its use in an unstable clinical setting can be safe and useful. This study sought to evaluate the results of coronary stenting in unstable angina and to determine patient, lesion and procedure-related predictors of 30-day and long-term ischemic events. METHODS We studied 266 consecutive patients (mean age 62 +/- 9 years) with unstable angina who underwent coronary artery stenting. The procedure was performed electively in 24%, in bailout situations in 11% and for a suboptimal result of conventional angioplasty in 65%. After stent implantation, patients were treated with anticoagulation (61) on combined antiplatelet therapy (200). Multivariate logistic regression analyses were performed to determine 30-day and long-term predictive factors of ischemic complications. RESULTS Procedural success was obtained in 261 patients (98.1%). During the first 30 days after stenting, one patient died from cardiogenic shock (0.3%) and six (22%) suffered a non-fatal Q-wave myocardial infarction. Patients with combined antiplatelet therapy had a significantly lower stent thrombosis rate (1.5% versus 11.4%, P = 0.002) than those treated with anticoagulant regimen. At long-term follow-up (17.7 +/- 9.4 months) cardiac mortality myocardial infarction and target-vessel revascularization rates were 0.4%, 1.5% and 9.3%, respectively. In multivessel and diabetic patients, a worse long-term event-free survival was observed. Logistic multivariate analysis revealed bailout stenting, anticoagulant therapy, implantation of stents longer than 15 mm as predictors of 30-day ischemic events. In addition, multivessel coronary artery disease and stent application with balloon size of less than 3 mm were predictive of long-term ischemic events. CONCLUSIONS This study demonstrates that, either electively or after failure of conventional angioplasty, coronary stenting represents an effective therapy for patients with unstable angina. In the same clinical setting, combined antiplatelet therapy is associated with a lower 30-day stent thrombosis rate than anticoagulant therapy. Bailout stenting, anticoagulant therapy, implantation of stents longer than 15 mm were shown to be predictors of 30-day ischemic events, whereas multivessel coronary artery disease and stent application with small balloon size were predictive of long-term ischemic events.

Angelo Branzi

Papers

Late Improvement in Ventricular Performance Following Internal Cardioversion for Persistent Atrial Fibrillation

Prophylaxis versus preemptive therapy for prevention of the consequences of cytomegalovirus infection in transplant recipients: a still unresolved issue.

New insights on pulmonary arterial hypertension

Contribution of morphology discrimination algorithm for improving rhythm discrimination in slow and fast ventricular tachycardia zones in dual-chamber implantable cardioverter-defibrillators.

Coronary stenting for unstable angina: predictors of 30-day and long-term clinical outcome.